Skip to content

Sham (software)-controlled, multicenter, dynamic allocation, double-blinded study of non-medication therapy with a software Yue in patients with insomnia disorders

Sham (software)-controlled, multicenter, dynamic allocation, double-blinded study of non-medication therapy with a software Yue in patients with insomnia disorders - Double-blinded study of non-medication therapy with a software Yue in patients with insomnia disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000032951
Enrollment
110
Registered
2018-06-11
Start date
2018-06-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia disorder

Interventions

non-medication therapy for 8weeks by application part of non medication therapy for 8weeks by application

Sponsors

Sustainable Medicine,Inc
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Insomnia disorder (ICSD-3). 2. Patients who can understand Japanese. 3. Patient who has smartphone.

Exclusion criteria

Exclusion criteria: 1. Patients with Athens Insomnia Scale (AIS) at the beginning of the trial less than 9 points. 2. Patients who have experienced drug treatment for insomnia within the past 14 days. 3. Patients without a sleeping diary since 7 days from the start of the trial. 4. Patients suspected or suffering from the following diseases. Mental illness Sleep apnea syndrome Sleep-related movement disorder Central hypersomnia Accompanying sleep Circadian rhythm disturbance alcoholism drug addiction cancer immune disease 5. Pregnant women, lactating women 6. Patients who are engaged in jobs requiring driving such as automobiles or motorbikes or jobs involving danger or scheduled to participate during the trial participation period.

Design outcomes

Primary

MeasureTime frame
Evaluation of Athens Insomnia Scale at 8 weeks from the start of treatment

Secondary

MeasureTime frame
KSS, QIDS, CGI-I, medication after completion of clinical trial

Countries

Japan,Asia(except Japan)

Contacts

Public ContactTakayuki Kojima

Sustainable Medicine,Inc Regulatory and Clinical research

takayuki.kojima@susmed.co.jp03-3527-3593

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026